Cypherpunk Technologies

Cypherpunk Technologies P/B

The P/B (Price-to-Book Ratio) of Cypherpunk Technologies (CYPH) as of Oct 17, 2026 is 1.15. In the previous year, P/B (Price-to-Book Ratio) was 0.67 — a change of 71.60% (higher).

P/B

1.15

YoY

71.60%

Last updated:

P/B (Price-to-Book Ratio) of Cypherpunk Technologies is 2024 1.15 . P/B (Price-to-Book Ratio) of Cypherpunk Technologies was 2023 0.67 . It decreases by 71.60% higher compared to the previous year.

The Cypherpunk Technologies P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2017
3.62 USD
Jan 1, 2018
4.38 USD
Jan 1, 2019
-22.99 USD
Jan 1, 2020
0.86 USD
Jan 1, 2021
0.37 USD
Jan 1, 2022
0.68 USD
Jan 1, 2023
0.67 USD
Jan 1, 2024
1.15 USD
The Cypherpunk Technologies P/B history
YEARP/BYoY
1.15+71.60%
0.67-2.12%
0.68+83.28%
0.37-56.76%
0.86-103.75%
-22.99-624.59%
4.38+21.17%
3.62-367.16%
-1.35-85.16%
-9.12-19.92%
-11.39—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cypherpunk Technologies Stock analysis

What does Cypherpunk Technologies do? Cypherpunk Technologies Inc, trading under the ticker CYPH, is a biotechnology company based in Cambridge, United States. The company has a small workforce of six employees. It went public with an IPO on January 24, 2017. The company's website is https://www.leaptx.com/. The source description provided by the user contains unverified information, including the company's headquarters in Cambridge, Massachusetts, and details about its clinical stage programs, which are not confirmed by the facts provided. The source also mentions the company having 24 employees, which contradicts the provided employee count of six. Additionally, the source describes the company as developing monoclonal antibodies targeting cancer pathways, but these details are not part of the verified facts. The company's actual focus and product pipeline remain unconfirmed based on the information given. The source also incorrectly identifies the company as Leap Therapeutics, Inc., which is not the official name provided. The website provided, https://www.leaptx.com/, appears to be related to Leap Therapeutics, not Cypherpunk Technologies Inc. Therefore, the description is limited to the verified facts: the company's name, ticker, ISIN, country, city, sector, industry, employee count, IPO date, and website. No additional details about products, programs, or specific therapeutic targets can be included due to lack of verified information. Cypherpunk Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cypherpunk Technologies stock

P/B (Price-to-Book Ratio) of Cypherpunk Technologies is 1.15 in 2024.

P/B (Price-to-Book Ratio) of Cypherpunk Technologies changed from 0.67 to 1.15, representing a 71.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Cypherpunk Technologies since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Cypherpunk Technologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Cypherpunk Technologies

All Key Metrics — Cypherpunk Technologies